The efficacy and tolerability of le

The efficacy and tolerability of levodopa/DDCI and entacapone therapy have been demonstrated in four prospective, randomized, double-blind, placebo-controlled Phase III studies performed in over 1000 patients with PD worldwide On this slide, the results of the NOMECOMT study are shown demonstrating a significant increase in ON-time and the results of the CELOMEN study are shown to demonstrate a significant decrease in OFF-time with levodopa/DDCI and entacapone therapy compared with conventional levodopa/DDCI therapy plus placeboMean daily ON-time was assessed by home diaries. At 6 months, the mean daily ON-time was increased by 1.2 hours compared with placeboMean daily OFF-time was assessed by home diaries. At 6 months, mean daily OFF-time was decreased by 1.6 hours in the entacapone-treated group compared with 0.9 hours in the placebo-treated groupSignificant improvements in patient function have also been observed with levodopa/DDCI and entacapone versus conventional levodopa/DDCI therapyIn the CELOMEN study, ADL scores improved in fluctuating patients treated with levodopa/DDCI and entacapone by –1.1 points and deteriorated with conventional levodopa plus placebo by 0.2 points. This difference between the groups was statistically significant (p